Internal Medicine, Hematology & Oncology · Flemington, NJ
NPI
1184612566
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2100 Wescott Dr
Flemington, NJ, 08822
Phone (908) 788-6461
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
130,574 services
Medicare patients, 2024
561
Average age 76
Drug cost, 2024
$6.6M
1,599 prescriptions
Company payments, 2025
$1,344
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth Blankstein was code J1439 (injection, ferric carboxymaltose, 1 mg), 21,000 times for 20 patients. In total Kenneth Blankstein billed 130,574 services in 146 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-12-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 21,000 | 20 | $0.87 | $18K |
| J0185 Injection, aprepitant, 1 mg | Office | 8,713 | 16 | $1.35 | $12K |
| J0897 Injection, denosumab, 1 mg | Office | 6,601 | 59 | $20.30 | $134K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 4,488 | 19 | $20.85 | $94K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 3,902 | 15 | $4.42 | $17K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,047 | 23 | $5.78 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,489 | 34 | $0.09 | $133 |
| 85025 Blood Count | Office | 1,245 | 385 | $7.61 | $9,474 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 915 | 13 | $3.49 | $3,197 |
| J9190 Injection, fluorouracil, 500 mg | Office | 626 | 13 | $2.28 | $1,429 |
| 99213 Office E&M - Established | Office | 618 | 304 | $72.68 | $45K |
| 99214 Office E&M - Established | Office | 618 | 242 | $101.94 | $63K |
| 96372 Injection Administration | Office | 484 | 141 | $12.38 | $5,990 |
| 80053 Clinical Chemistry | Office | 452 | 220 | $10.35 | $4,678 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 417 | 16 | $0.07 | $30.51 |
By year: 2022 $2.4M for 181,758 services; 2023 $1.9M for 154,760 services; 2024 $2.1M for 130,574 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,245 | 385 | $7.61 | $9,474 |
| 80053 Clinical Chemistry | 452 | 220 | $10.35 | $4,678 |
| 83615 Clinical Chemistry | 379 | 193 | $5.92 | $2,244 |
| 36415 Venipuncture Blood Collection | 361 | 206 | $8.65 | $3,123 |
| 82378 Clinical Chemistry | 178 | 84 | $18.58 | $3,307 |
| 84100 Clinical Chemistry | 134 | 75 | $4.65 | $623 |
| 83735 Clinical Chemistry | 132 | 74 | $6.57 | $867 |
| 86300 Immunoassay | 92 | 52 | $20.39 | $1,876 |
| 84153 Clinical Chemistry | 47 | 19 | $18.02 | $847 |
| 84443 Clinical Chemistry | 37 | 22 | $16.46 | $609 |
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth Blankstein prescribed most often to Medicare patients was Anastrozole, with 237 prescriptions and refills. In total Kenneth Blankstein wrote 1,599 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 237 | 622 | 58 | $6,379 |
| Tamoxifen Citrate Generic | 73 | 169 | 18 | $1,345 |
| Procrit Epoetin Alfa | 65 | 65 | 16 | $271K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 51 | 51 | Under 11 | $779K |
| Letrozole Generic | 48 | 84 | Under 11 | $818 |
| Prednisone Generic | 34 | 37 | 15 | $279 |
| Revlimid Lenalidomide | 31 | 31 | Under 11 | $549K |
| Ondansetron Hcl Generic | 26 | 26 | 11 | $300 |
| Brukinsa Zanubrutinib | 26 | 26 | Under 11 | $369K |
| Dexamethasone Generic | 25 | 27 | Under 11 | $330 |
| Erleada Apalutamide | 24 | 24 | Under 11 | $350K |
| Lupron Depot Leuprolide Acetate | 23 | 84 | Under 11 | $163K |
| Azacitidine Generic | 23 | 23 | Under 11 | $81K |
| Xarelto Rivaroxaban | 22 | 38 | Under 11 | $20K |
| Acyclovir Generic | 22 | 52 | Under 11 | $528 |
Brand drugs: 634 claims; generic drugs: 945 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth Blankstein $1,344 ($1,344 in general payments such as food, travel and fees) from 33 companies. The largest payer was Daiichi Sankyo Inc. with $181.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 9 | $181 |
| Pfizer Inc. PFE | 7 | $132 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $116 |
| GlaxoSmithKline, LLC. GSK | 5 | $98.64 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $90.73 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $70.83 |
| Abbvie Inc. ABBV | 3 | $51.52 |
| Genzyme Corporation SNY | 2 | $38.27 |
| BeiGene USA, Inc. ONC | 2 | $37.7 |
| Stemline Therapeutics Inc. | 2 | $36.89 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.